Company Overview and News
KUALA LUMPUR (Oct 5): The FBM KLCI fell 0.38% at mid-morning today, tracking fragile regional markets.
UPBMF 7113 TPGVF BATS 4162 2291 5202 2089 9334 6033 9113 4634 TGLVY 5139 PNADF 5226 3301 NDAQ 0900 6888 5819 AXXTF 1902 PNAGF
Late Friday last week, little known Pinehill Pacific Bhd (formerly known as Multi Vest Resources Bhd, which by the way was formerly known as Best World Land Bhd) surprised the market with the announcement that it was parting with nearly 9,000 acres of landbank and related plantation assets held via three subsidiary companies to United Plantations Bhd (UP) for a whopping sum of RM413.6mil.
2038 5138 1996 UPBMF 4383 7501 1902 2089 5112
Pinehill Pacific Bhd (+ve) Trading of shares in Pinehill Pacific Bhd (fundamental: 0/3, valuation: 0.9/3) fell by 8.5 sen or 15.74% to 45.5 sen yesterday, after 14.3 million shares were traded, versus the counter’s 200-day average volume of about 192,248 shares.
UPBMF 1902 2089
KUALA LUMPUR (Sept 25): The FBM KLCI pared some of its loss at midday break today, against a backdrop of struggling regional markets.
HLFBF BRDBF 7036 1082 5681 6432 BATS 4162 7374 5256 5199 5210 1783 5029 3867 SGPBY 6888 AXXTF 5827 1902 HIPEF GEBHF 3719
KUALA LUMPUR (Sept 24): The FBM KLCI fell 0.57% at the midday breakin line with the tumble at most regional markets after China called off the trade talks with US officials.
APEXF 7090 UPBMF 5031 5202 2089 9334 6033 7123 5199 KLKBY 2445 PNADF 5347 3026 3867 0026 TNABY 5819 2836 1902 TNABF HIPEF PNAGF
KUALA LUMPUR, Sept 24 — Share prices on Bursa Malaysia opened lower today, in line with most regional bourses, with investors cautious over the latest development in the US-China trade dispute, dealers said.
PBLOF 7036 0070 1902 1295 BSMAF 1818
KUALA LUMPUR (Sept 24): Shares in Pinehill Pacific Bhd jumped 40.91% in active trade this morning following the announcement of the group's disposal of 8,999.13 acres of land in Daerah Hilir Perak to United Plantations Bhd for RM413.57 million cash.
UPBMF 1902 2089
KUALA LUMPUR (Sep 21): Based on corporate announcements and news flow today, stocks in focus for Monday (Sep 24) may include the following: Malaysia Airports Holdings Bhd, United Plantations Bhd, Utusan Melayu (Malaysia) Bhd, Telekom Malaysia Bhd, Binasat Communications Bhd, KESM Industries Bhd, NTPM Holdings Bhd, Country Heights Holdings Bhd and MNRB Holdings Bhd.
UPBMF 5066 5088 2089 5014 9334 5754 4863 5738 6459 MYPRY MYTEF 1902
KUALA LUMPUR (Sept 21): Shares in Pinehill Pacific Bhd hit limit up after the stock rose as much as 30 sen or 214.29% to 44 sen after resuming trading from 2.30pm today. Trading in its shares was halted this morning pending the announcement of the group's disposal of 8,999.13 acres of land in Daerah Hilir Perak to United Plantations Bhd for RM413.57 million cash.
UPBMF 1902 BSMAF 2089 1818
KUALA LUMPUR (Sept 21): United Plantations Bhd is acquiring seven pieces of agricultural land totalling 8999.13 acres in Daerah Hilir Perak, together with palm oil mill, workers; living quarters and a site office, from Pinehill Pacific Bhd’s group of companies for RM413.57 million in cash.
UPBMF 1902 BSMAF 2089 1818
KUALA LUMPUR (Sept 20): Shares of Pinehill Pacific Bhd will be suspended from trading with effect from 9am tomorrow (Friday, Sept 21) pending the release of a material announcement, the palm oil player said in a filing with Bursa Malaysia today.
1902 BSMAF 1818
KUALA LUMPUR: The trading of shares in Pinehill Pacific Bhd (PinePac) will be suspended on Friday to make way for a material announcement, the company said in a filing with Bursa Malaysia.
1902 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...